Eric Joseph
Stock Analyst at JP Morgan
(2.07)
# 3,046
Out of 5,090 analysts
125
Total ratings
38.82%
Success rate
-4.31%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $31.46 | +55.75% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $29.01 | +58.57% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $66.56 | -3.85% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.42 | +104.98% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.85 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $6.84 | +2.41% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $77.83 | -13.91% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.35 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.30 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $18.00 | +66.67% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $6.87 | +103.93% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $78.51 | -9.56% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $26.17 | +45.23% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $3.41 | +574.49% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.56 | +124.87% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $8.00 | +162.66% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.17 | -29.43% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.17 | +1,177.36% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.60 | +130.77% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.89 | +104.71% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $17.27 | -36.31% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $54.59 | -24.89% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $25.38 | +294.01% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.52 | +855.11% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.10 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $27.21 | -59.57% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $18.39 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $5.89 | +1,937.35% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $10.17 | +2,849.85% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.98 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.57 | +473.25% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.60 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.71 | +1,450.50% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.71 | +250.40% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.54 | +1,954.16% | 3 | Nov 14, 2018 |
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $31.46
Upside: +55.75%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $29.01
Upside: +58.57%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $66.56
Upside: -3.85%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.42
Upside: +104.98%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.85
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $6.84
Upside: +2.41%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $77.83
Upside: -13.91%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.30
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $18.00
Upside: +66.67%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $6.87
Upside: +103.93%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $78.51
Upside: -9.56%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $26.17
Upside: +45.23%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $3.41
Upside: +574.49%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.56
Upside: +124.87%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $8.00
Upside: +162.66%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $14.17
Upside: -29.43%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.17
Upside: +1,177.36%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.60
Upside: +130.77%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.89
Upside: +104.71%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $17.27
Upside: -36.31%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $54.59
Upside: -24.89%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $25.38
Upside: +294.01%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.52
Upside: +855.11%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.10
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $27.21
Upside: -59.57%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $18.39
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $5.89
Upside: +1,937.35%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $10.17
Upside: +2,849.85%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $10.98
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.57
Upside: +473.25%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.60
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.71
Upside: +1,450.50%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.71
Upside: +250.40%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.54
Upside: +1,954.16%